ARYx Therapeutics reviews net loss of $5.
ARYx Therapeutics reviews net loss of $5.8M for fourth-quarter 2009 ARYx Therapeutics, Inc. today reported outcomes of procedures and provided an revise on its items for the fourth one fourth and season ended December 31, 2009 genericcialis.net . 2009 was a year of mixed outcomes for ARYx. We continuing to progress with the development of our three business lead product candidates towards achievement of the target profiles we’d set for them. Nevertheless, the consequence of not completing a licensing contract for budiodarone, our novel antiarrhythmic agent, to a large pharmaceutical business left ARYx in a difficult situation. We dedicated in February 2010 to optimize the value in the near-term that people believe exists for every of our product candidates by retaining Company and Cowen, an investment lender, to explore strategic alternatives. (more…)